The EU and White House reveal new trade details impacting pharmaceutical and auto industries. US to cap tariffs on pharmaceutical imports at 15% and lower tariffs on car manufacturers to 15% once EU removes tariffs on seafood and agricultural products. Key stocks like Novo Nordisk and Stellantis react differently to the news.

US trade deficit with the eurozone focuses on goods, with a $236 billion deficit in 2024 from high-value products like consumer goods and cars. EU agrees to buy more US goods, including energy, in exchange for tariffs on pharmaceutical exports. US shows a more pragmatic approach to tariffs, exempting goods it cannot produce domestically.

European pharmaceutical and auto stocks react to new tariff details between the EU and US. Investors gain clarity on US stance towards pharmaceutical industry. Trump’s agreement with the EU benefits Europe and pharmaceutical firms. European carmakers face challenges in the electric vehicle market and regulatory issues.

Read more at Morningstar UK: Latest EU Tariff Details Overall Positive for Europe Stocks